Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors (PIVOT-02)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02983045
Recruitment Status : Completed
First Posted : December 6, 2016
Last Update Posted : June 24, 2022
Bristol-Myers Squibb
Information provided by (Responsible Party):
Nektar Therapeutics

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : April 28, 2022
Actual Study Completion Date : April 28, 2022